Ceftiaxone-induced neurotoxicity: case report, pharmacokinetic considerations, and literature review
- PMID: 22969263
- PMCID: PMC3429834
- DOI: 10.3346/jkms.2012.27.9.1120
Ceftiaxone-induced neurotoxicity: case report, pharmacokinetic considerations, and literature review
Abstract
Ceftriaxone is widely used in patients for the treatment of serious gram-negative infections. Ceftriaxone can induce some potential side effects, including neurotoxicity, however, nonconvulsive status epilepticus has rarely been reported. We report a case of acute reversible neurotoxicity associated with ceftriaxone. A 65-yr-old woman with chronic kidney disease developed altered consciousness during ceftriaxone treatment for urinary tract infection. The electroencephalogram demonstrated continuous bursts of generalized, high-voltage, 1 to 2 Hz sharp wave activity. Neurologic symptoms disappeared following withdrawal of ceftriaxone. The possibility of ceftriaxone-induced neurotoxicity should be considered in patients developing neurological impairment during ceftriaxone use, and the discontinuation of the drug could lead to complete neurological improvement.
Keywords: Ceftriaxone; Cephalosporins; Chronic Kidney Failure; Seizures.
Figures


Similar articles
-
Ceftriaxone-induced Neurotoxicity in a Patient after Pancreas-Kidney Transplantation.Intern Med. 2017 Nov 15;56(22):3103-3107. doi: 10.2169/internalmedicine.8774-16. Epub 2017 Sep 25. Intern Med. 2017. PMID: 28943562 Free PMC article.
-
Ceftriaxone-induced acute reversible encephalopathy in a patient treated for a urinary tract infection.Neth J Med. 2009 Feb;67(2):72-5. Neth J Med. 2009. PMID: 19299850
-
Ceftriaxone-associated encephalopathy in a patient with high levels of ceftriaxone in blood and cerebrospinal fluid.Int J Infect Dis. 2022 Mar;116:223-225. doi: 10.1016/j.ijid.2022.01.023. Epub 2022 Jan 19. Int J Infect Dis. 2022. PMID: 35063677
-
Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review.Pharmacotherapy. 2006 Aug;26(8):1169-74. doi: 10.1592/phco.26.8.1169. Pharmacotherapy. 2006. PMID: 16863493 Review.
-
Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring.Ann Pharmacother. 2008 Dec;42(12):1843-50. doi: 10.1345/aph.1L307. Epub 2008 Nov 25. Ann Pharmacother. 2008. PMID: 19033476 Review.
Cited by
-
Reversible Choreoathetosis in a Patient with End-stage Renal Disease from Administration of Ceftriaxone.Cureus. 2019 Sep 25;11(9):e5764. doi: 10.7759/cureus.5764. Cureus. 2019. PMID: 31723523 Free PMC article.
-
Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.Front Pharmacol. 2023 Jul 20;14:1200828. doi: 10.3389/fphar.2023.1200828. eCollection 2023. Front Pharmacol. 2023. PMID: 37547336 Free PMC article.
-
Ceftriaxone encephalopathy in a very elderly dialysis patient.CEN Case Rep. 2025 Jun;14(3):312-317. doi: 10.1007/s13730-024-00953-4. Epub 2024 Dec 9. CEN Case Rep. 2025. PMID: 39653878 Free PMC article.
-
Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review.Drug Saf. 2017 Dec;40(12):1171-1198. doi: 10.1007/s40264-017-0578-2. Drug Saf. 2017. PMID: 28755095
-
Infectious stress triggers a POLG-related mitochondrial disease.Neurogenetics. 2020 Jan;21(1):19-27. doi: 10.1007/s10048-019-00593-2. Epub 2019 Oct 26. Neurogenetics. 2020. PMID: 31655921
References
-
- Rockowitz J, Tunkel AR. Bacterial meningitis. Practical guidelines for management. Drugs. 1995;50:838–853. - PubMed
-
- Weisfelt M, de Gans J, van de Beek D. Bacterial meningitis: a review of effective pharmacotherapy. Expert Opin Pharmacother. 2007;8:1493–1504. - PubMed
-
- Martinez-Rodriguez JE, Barriga FJ, Santamaria J, Iranzo A, Pareja JA, Revilla M, dela Rosa CR. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med. 2001;111:115–119. - PubMed
-
- Sato Y, Morita H, Wakasugi H, Iijima S, Kawashima E, Wakayama Y, Yoshimura A. Reversible chreoathetosis after the administration of ceftriaxone sodium in patients with end-stage renal disease. Am J Med Sci. 2010;340:382–384. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical